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Abstract 
Antibiotic release from a carrier can be employed to reduce the frequency of administration or 
prolong efficacy. In this work, we prepared silica nanoparticles loaded with gentamicin through 
different synthetis routes (entrapment, adsorption, covalent bonding and Layer-by-Layer (LbL) 
techniques). The nanocarriers physical-chemical properties were characterised and antibiotic release 
from the nanocarriers was monitored. The nanoparticles prepared entrapping gentamicin gave the 
highest drug load but completed the release over a period of 4 hours. No significant differences in 
antibiotic load were noticed between absorption or  binding of gentamicin onto the silica 
nanoparticles surface; moreover the release of the drug occurred over 2 days. The nanoparticles 
coated with gentamicin through LbL technique released the antibiotic for 3 weeks. This work 
demonstrates that silica nanoparticles can be employed as antibiotic carriers providing a continuous 
release of antibiotic over a period that can be tuned through the choice of preparation method. 
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1 Introduction 
Research on local delivery of antibiotic became more insistent as this approach would achieve 
high drug concentration where needed simultaneously avoiding the systemic side effects of 
antibiotics [1]; an additional benefit would be the reduction of antibiotic sub-lethal levels that are a 
known factor in the development of resistance towards these drugs [2].  These hypotheses have 
been experimentally confirmed as enhanced outcome have been reported when antibiotic delivery 
has been modulated through drug delivery systems [3]-[7]. 
Drug delivery systems for antibiotics can be prepared through the tethering of the molecule to a 
surface [8]-[10] or to a particle [11]-[14]. Alternatively, the drug can be encapsulated inside either 
nanoparticles [15] or liposomes [16]; another option is for the drug to be deposited onto a surface 
using Layer-by-layer (LbL) [17],[18]. 
Layer-by-layer is a self-assembly coating technique originally developed using polyelectrolytes 
of opposite charges alternately adsorbed onto a charged surface; after the deposition of each layer, 
the surface charge is reversed [19]. Moreover, uncharged materials like hydrophobic polymers can 
build up layers in LbL as formation forces are not limited to electrostatic interactions and almost 
every type of charged molecule or material can be used; examples are organic dyes, biological 
polysaccharides, polypeptides, DNA, proteins and antibiotics [20]. Also hydrophobic interactions, 
hydrogen bonding, charge transfer, covalent binding or biological recognition can supply the 
required attraction forces [20]. In addition to pharmaceutical applications, LbL method is often used 
in optical systems, sensors and biosensors, electronic devices and for surface protection  [21]. 
Pharmaceutical research has employed LbL systems such as coating of particles [24], surfaces [25] 
and liposomes [26]; the coating of surfaces has been particular successful in prevent biofilm 
formation [27],[28]. Drugs can be added to the LbL system in different ways. The drug can be part 
of the coated layers (reservoir system) as one of the deposited layers instead of a polyelectrolyte or 
conjugated to one of the polyelectrolytes [28]; moreover the active molecule can be encapsulated 
within the polyelectrolyte shell after core dissolution (matrix system) [24],[30]. LbL systems have 
been employed to prolong release [31], improve dissolution of hydrophobic drugs [33] and to 
improve cell targeting. The drug release profile can be influenced by the number of layers, the 
attraction forces between the different layers and the temperature [24]; whilst the release can 
triggered by pH [32], light [35] or sound [36]. 
Silica nanoparticles are well established drug carriers as they are extremely blood compatible 
[37]-[39] and their properties can be easily modified for the purpose of drug loading, controlled 
release and targeting characteristics [40]. Surface modification of nanoparticles can be performed in 
order to alter retention properties or to provide moieties for the further binding of active molecules 
[41]. The release profile, for example, is strongly influenced by loading capacity, surface properties 
and pore size of the nanoparticles [40].  
Gentamicin is a large-spectrum antibiotic belonging to the aminoglycoside class; antibacterial 
activity is due to its ability to irreversibly bind ribosomes and halt proteins synthesis [42]. 
Gentamicin is employed to treat various infections such as topical, orthopeadic and ocular [43] and 
is used here as model antibiotic.     
We hypothesised that silica nanoparticles loaded with antibiotics could be prepared through 
different synthetis routes resulting in different level of drug loading and different release kinetics. In 
this work, silica nanoparticles containing gentamicin have been prepared (1) entrapping the 
molecule inside the nanoparticles during synthesis; (2) adsorbing the antibiotic on the surface of 
nanoparticles either unfuctionalised or after surface functionalisation with amino or carboxyl 
groups; (3) covalently binding the drug molecule to amino or carboxyl functionalised nanoparticles 
and (4) coating the particles using the Layer-by-Layer technique (Figure 1). The chemical-physical 
properties of each type of nanoparticles have been determined and the release profiles established. 
Depending on the preparation method, the active release period can vary from a few hours to 3 
weeks; therefore, fulfilling the requirements of different applications.  
 2 Experimental 
2.1 Chemicals 
Gentamicin sulphate, tetraethyl-orthosilicate (TEOS), 3-aminopropyltriethoxysilane (APTS), 2-
(4-morpholino)-ethane sulfonic acid (MES), suberic acid bis-(N-hydroxy-succinimide ester), ortho-
phthaldialdehyde reagent solution (OPA), sodium alginate (Mw 80.000-120.000 Da) and chitosan 
(Mw 190.000-310.000 Da) were purchased from Sigma-Aldrich. Triton X-100, ammonium 
hydroxide (29.6 %), cyclohexane, n-hexanol, Dichloromethane (DCM), isopropyl alcohol and 
methanol were purchased from Fisher Scientific. All chemicals were used as-received. 
2.2 Synthesis silica-antibiotic nanocarriers 
Silica nanoparticles (SiO2) were prepared by hydrolysis of TEOS in reverse microemulsion. In a 
typical synthesis, 17.7 g of Triton X-100 were mixed with 16 ml of n-hexanol, 75 ml of 
cyclohexane and 4.8 ml of deionised water under vigorous stirring. Once the solution became 
transparent, 600 μl of ammonium hydroxide (29.6 %) were added. The solution was subsequently 
sealed and stirred for further 20 min, followed by addition of 1 ml of TEOS and stirring for 24 h. 
The SiO2 nanoparticles were then recovered by adding ethanol (200 ml) to break the microemulsion 
and centrifuging at 3256 g for 10 min (LE-80K Ultracentrifuge, Beckman Coulter, UK) at 20 °C, 
the nanoparticles were then vigorously washed with methanol and DI water. 
The silica nanoparticles surface were functionalized, when required, with amine groups adding 50 
μl of APTS after 24 hours from the beginning of the synthesis to the microemulsion and incubating 
further 24 hours under stirring. The SiO2-NH2 nanoparticles were then recovered by adding ethanol 
(200 ml) to break the microemulsion and centrifuging at 3256 g for 10 min (LE-80K 
Ultracentrifuge, Beckman Coulter, UK) at 20 °C, the nanoparticles were then vigorously washed 
with methanol and DI water. 
2.2.1 Entrapment of gentamicin into the silica nanocarriers 
These nanoparticles were prepared as described above employing deionised water containing 
gentamicin sulphate (86 mg). 
2.2.2 Succinylation silica nanocarriers 
Amino functionalised nanoparticles (250 mg) and succinic anhydride (25 mg) were dispersed in 
DCM (100 ml). The suspension was purged with nitrogen and kept under vigorous stirring for 
24 hours. DCM was evaporated under vacuum at room temperature. The succinylated nanoparticles 
(SiO2-COOH) were washed three times with methanol and dried on a watch glass over night at 
room temperature. 
2.2.3 Conjugation of gentamicin onto the silica nanocarriers 
The conjugation of gentamicin to SiO2-NH2 nanoparticles was carried out as follows: 50 mg of 
antibiotic were dissolved in 100 ml of MES buffer (0.1 M, pH 6.0); this solution was used to 
disperse 250 mg of SiO2-NH2 and finally 5 mg of suberic acid bis-(N-hydroxysucciniimide ester) 
were added. The suspension was kept under vigorous mixing for 24 hours and then the conjugates 
were recovered centrifuging 3256 g for 10 min (LE-80K Ultracentrifuge, Beckman Coulter, UK) at 
20 °C. The silica-antibiotic conjugates were washed three times in methanol and left to dry. 
The conjugation of gentamicin to SiO2-COOH nanoparticles was carried out as follows: 
Gentamicin sulphate (50 mg) was dissolved in 100 ml of MES buffer (0.1 M, pH 6). This solution 
was used to disperse succinylated nanoparticles (250 mg), 10 mg of N-hydroxysuccinimide (NHS) 
10 mg of 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDC). The suspension 
was kept under vigorous stirring for 24 hours. The conjugates were recovered by centrifuging at 
3256 g for 10 min (LE-80K Ultracentrifuge, Beckman Coulter, UK) at room temperature. After, the 
nanoparticles were washed three times with methanol. The nanoparticles were dried on a watch 
glass over night at room temperature. 
2.2.4 Adsorption of gentamicin onto the silica nanocarriers 
Gentamicin sulphate (50 mg) was dissolved in 100 ml of MES buffer (0.1 M, pH 6). This solution 
was used to disperse the different nanoparticles (250 mg). The suspension was kept under vigorous 
stirring for 24 hours. The adsorbed nanoparticles were recovered by centrifuging at 3256 g for 
10 min (LE-80K Ultracentrifuge, Beckman Coulter, UK) at room temperature. Then the 
nanoparticles were washed three times with methanol and dried on a watch glass over night at room 
temperature. 
2.2.5 Layer-by-layer deposition of gentamicin on silica nanocarriers 
Dipping solutions were prepared in 100mM sodium acetate buffer pH = 5; alginate and chitosan 
were prepared at 2 mg/ml whilst gentamicin was prepared at 10 mg/ml. 
About 250 mg of amino functionalised nanoparticles (SiO2-NH2) were dispersed in 25 ml of 
alginate solution and vortexed for 10 min. Particles were separated through centrifugation at 3256 g 
for 10 min. The supernatant was removed and the particles washed through redispersion in fresh 
acetate buffer pH = 5 and centrifuged at 3256 g for 10 min (LE-80K Ultracentrifuge, Beckman 
Coulter, UK). After discharging the supernatant, another layer was deposited dispersing the 
particles in gentamicin solution (25 ml) and vortexing for 10 min. The centrifugation/washing 
protocol was repeated and then again the particles were vortexed in alginate for 10 min. After 
repeating the centrifugation/washing protocol the particles were dispersed in chitosan for 10 min 
with vortexing. Finally, the particles were centrifuged, washed with clean buffer, deposited onto a 
glass watch and left to dry in a fume hood. 
 
2.3 Silica-antibiotic nanocarriers characterisation 
2.3.1 Transmission electron microscopy (TEM) 
Size and shape of the conjugates was determined through transmission electron microscopy 
(TEM); 4 µl droplet of conjugates suspension were deposited on a plain carbon-coated copper TEM 
grid, water was evaporated under ambient laboratory conditions for several hours. Bright field TEM 
images were obtained using a TEM (Philips CM12, FEI Ltd, UK) operating at 80kV fitted with an 
X-ray microanalysis detector (EM-400 Detecting Unit, EDAX UK) utilising EDAX’s Genesis 
software. Images (magnification of the images was x 100000) were recorded using a SIS 
MegaView III digital camera (SIS Analytical, Germany) and analysed with ImageJ; the diameter of 
at least 100 particles was determined for each type of nanoparticles. 
2.3.2 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a Stanton Redcroft, STA-780; data were 
recorded from 25 to 600 °C with a constant heating rate of 10 °C min-1. 
2.3.3 Brunauer–Emmett–Teller (BET) 
Nitrogen adsorption-desorption isotherms were used to determine porosity and specific surface 
area of the silica nanoparticles. Isotherms at 77 K were obtained using BET Analyser, NOVA-e™ 
Series (Quantochrome Instruments, USA). Before starting the adsorption measurements, all silica 
samples were degassed under vacuum at 80° C for 4 h. The BET surface was calculated through the 
MultiPoint BET model using the instrument software. The total pore volume was determined for 
pores with a radius less than 405 Å at P/Po = 0.97 by the instrument software.  
2.3.4 Zeta potential 
Approximately 2 mg sample were dispersed in 1 ml of buffer solution at the chosen pH. The 
suspension was vortexed and transferred to a capillary cell. The zeta potential was measured 
immediately using Zetasizer ZEN 3600, Nano Series (Malvern, UK). For pH = 4 and 5, an acetic 
buffers (0.1 M) were prepared, whereas phosphate buffer (0.1 M) was employed for pH = 7. The 
highest pH value was achieved with a glycine buffer pH = 9 (0.1 M). 
 2.4 Gentamicin release  
Gentamicin release was quantified dispersing conjugates (5 mg) in 1 ml of NaH2PO4 - Na2HPO4 
buffer at pH = 7.4 and 5; the suspensions were kept in eppendorf and incubated at 37 °C. At 
prefixed times, samples were centrifuged and the supernatant collected for antibiotic quantification, 
the particles were resuspended in 1 ml of the corresponding buffer and incubated at 37 °C. 
Gentamicin was quantified thorough fluorescence spectroscopy using o-phthaldialdehyde (OPA); 
100 l of buffer containing antibiotic were mixed with 100 l of iso-propanol and 100 l of OPA 
reagent; after 30 min at room temperature in the dark, 200 l of the mixture were transferred in a 
black 96 wells plate and the fluorescence determined (excitation wavelength = 340 nm and 
emission wavelength = 450 nm) with a fluoroscan (FLUOROstar Optina, BMG Labtech); standards 
of known gentamicin concentration were also analysed simultaneously to provide calibration. 
All characterisations were carried out on nanoparticles obtained from at least three independent 
batches; results are presented as mean ± standard deviation. 
  
3 Results  
The silica nanoparticles unconjugated (SiO2) appeared spherically shaped (Figure 2) with a 
narrowly distributed diameter. The particles diameters population distribution was closely modelled 
by a Gaussian model with a mean of 55.5 nm and a standard deviation of 6.6 nm. Surface 
functionalisation, gentamicin conjugation or absorption along with LbL deposition did not have 
effect on these parameters (data not shown).  
Examples of adsorption and desorption curves of nitrogen on the nanocarriers are presented in 
Figure 3 were differences between unfunctionalised nanoparticles and nanocarriers with entrapped 
gentamicin are evident. The BET parameters are summarised in Table 1 and revealed that the pore 
size of the particles was affected only by the entrapment of gentamicin. The functionalisation also 
resulted in a reduced BET surface area but further conjugation/adsorption did not affect either 
surface area or pores size of the nanocarriers. 
During TGA analysis (Figure 4) all particles exhibited a weight loss of about 8-10% in the 
temperature range 20-100 °C; with increasing temperature the weight loss of the samples increased 
monotonically reaching a plateau after about 600°C. Unfunctionalised and unloaded nanoparticles 
(SiO2) returned a weight loss of 14%. this was the lowest of all samples (Table 1), whilst the 
nanocarriers with entrapped gentamicin had the greatest weight loss (31%). Nanoparticles loaded 
with gentamicin had the same mass loss regardless of the fact that the antibiotic was either 
conjugated or adsorbed; for both silica functionalised with amino groups (SiO2-NH2) or with 
carboxyl groups (SiO2-COOH), the weight loss increased when the nanocarriers were loaded with 
gentamicin, from 17 to 19 %. 
The zeta potentials of the silica nanoparticles at pH values ranging from 4 to 9 are shown in 
Figure 5; in all cases the zeta potential decreased with increasing pH. Unfunctionalised nanocarriers 
had a negative charge throughout the pH range tested regardless of the presence of adsorbed 
gentamicin. Particles with entrapped antibiotic exhibited a slightly higher zeta potential than the 
corresponding unloaded nanocarriers. Amino functionalised silica nanoparticles had a remarkably 
high positive zeta potential (about +40 mV) at pH = 4 and 5; this decreased towards neutrality when 
pH increased to 7 and 9. The presence of gentamicin decreased the zeta potential compared to the 
unloaded particles with not significant differences between adsorbed or conjugated antibiotic at all 
pHs tested but 9. Silica nanoparticles functionalised with carboxyl acid groups had a positive zeta 
potential at pH = 4 while at more alkaline pH values the zeta potential was negative. The 
conjugation or adsorption of gentamicin resulted in higher zeta potential values through the pH 
range tested.   
The percentage of gentamicin released from the nanocarriers over time in buffer at pH = 5 and 7.4 
is shown in (Figure 6). When gentamicin was entrapped in the silica nanoparticles, not all the 
antibiotic was able to leave and the release occurred in the first 4 hours, the maximum amount of 
gentamicin was higher at pH = 5 than at pH = 7.4. Unfunctionalised nanoparticles with adsorbed 
gentamicin released very little antibiotic in the first few hours and no more after this regardless of 
the pH tested. Functionalised silica nanoparticles both with amino and carboxyl groups exhibited a 
sustained release of antibiotic for at least 2 days. No significant difference was found between 
adsorption and conjugation method of loading gentamicin onto the nanocarriers. The kinetic of 
release was quicker at pH = 7.4 than at pH = 5.  
During LbL deposition the organic content of the nanocarriers increased after each layer as shown 
by the TGA thermograms (Figure 7a), additionally the surface charge initially positive became 
negative after the deposition of the alginate layers and positive after the deposition of chitosan 
(Figure 7b). After the deposition of gentamicin the surface charge was mildly positive. The release 
of antibiotics from silica nanocarriers prepared through LbL continued for 3 weeks and was affected 
by the pH of the solution (Figure 7b). 
 
4 Discussion 
The Stöber synthetic method for silica nanoparticles is based on the hydrolysis of TEOS (soluble 
in water) in an water in oil emulsion; because of the nanoparticles growth occurs inside the water 
droplet, the final size and shape of synthesised nanoparticles depends on the size and shape of water 
droplets [44]. The variation of the organic solvent and of the other reaction conditions has been 
successfully employed to prepare silica nanoparticles in a wide range of sizes. Our results (Figure 2) 
are consistent with other works employing the same reagents and conditions [48]; furthermore the 
limited number of polyelectrolytes layers deposited onto the nanocarriers during LbL was no 
sufficient to increase the average particle diameter. Because of the mechanism of synthesis of the 
nanoparticles, entrapment of the antibiotic had no effect on size of the nanocarriers; however when 
gentamicin was present in the water phase, the growth of the silica particles was disturbed by the 
antibiotic resulting in nanoparticles with higher surface area (Table 1 and Figure 3). The adsorption-
desorption curves of N2 (Figure 3) depict a typical Type II profile confirming the lack of mesopores 
in the nanocarriers. Furthermore, the lower amount of N2-adsorbed/desorbed by the nanocarriers 
with entrapped gentamicin compared to the other carriers, along with the lower values of total pore 
volume, suggests that the antibiotic is entangled inside the network of silane-oxygen bonds as 
suggested by Capeletti et al. [15] and Hakeem et al. [49]. Moreover, as gentamicin partitions 
predominately in the aqueous phase, the nanocarriers prepared through this protocol had the highest 
load of antibiotic. Similar loading results were reported for the encapsulation of vancomycin in 
mesoporous silica nanoparticles [15]. The functionalisation of the nanoparticles, the adsorption or 
conjugation of the antibiotic or the LbL deposition are processes affecting only the outer surface of 
the nanoparticles thus they did not impact the overall size and shape of the carriers. Likewise, these 
processes were also unable to impact the porosity of the nanoparticles, on the contrary they reduced 
the surface area of the nanocarriers available for gas adsorption as seen in the BET analysis (Table 
1 and Figure 3); this was in consequence of the presence of the antibiotic on the surface that 
reduced the active sites for gas adsorption.  
TGA is routinely employed to quantify the organic and inorganic fraction of substrates. At 
temperatures below 100 °C (Figure 4) the weight loss shown by the samples is related to water 
adsorbed, at higher temperatures the weight loss depends on the organic fraction presents on the 
nanoparticles. The unfunctionalised nanoparticles exhibited almost no organic fraction; this was 
expected as only silane and oxygen were present in this samples. Whereas both the amino and 
carboxyl acid functionalised carriers presented weight loss greater than unfuctionalised particles in 
virtue of either the amino propyl-silane used to coat the surface of the bare silica nanoparticles or 
the subsequent succinylation. The higher weight losses exhibited by the samples with gentamicin 
are consistent with the successful load of the carriers with the antibiotic. The loading protocols 
through adsorption or conjugation, returned similar weight losses; hence the efficiency of the two 
approaches was comparable. 
The charge exhibited by the particles, and expressed through the zeta potential, depends on the 
balance between the protonated and the unprotonated groups present on the surface. Such balance is 
influenced by the pH of the solution; for example, amino groups are positively charged at low pHs 
values because of the protonation of the nitrogens while they are neutral at high pHs. On the other 
hand, carboxyl groups are negatively charged at high pHs in virtue of the protonation of the 
hydroxyl groups at low pHs. The pH resulting in half of the groups protonation (and half of the 
groups deprotonation) corresponds to the value of pKa of the dissociation reaction (Henderson - 
Hasslbach equation). Cells are generally negatively charged hence strong electrostatic interactions 
would be originated towards positively charged particles, however surfaces appendices present on 
cell can overcome the possible repulsive barrier observed when facing negatively charged surfaces; 
evidence has shown that positively nanoparticles have higher toxicity than negatively charged ones 
[45]. Human body pH is generally close to neutral, however there are some fluids that exhibit 
extreme acidity (stomach is about pH = 3.5 [46]) or alkalinity (pancreatic fluid is about pH = 8.8 
[47]) therefore the pH range employed for our studies covers such spectrum. Unfunctionalised 
particles exhibit hydroxyl groups on the surface that behave as weak acid; hence they are protonated 
and nearly neutral at pH values up to about 7, while they are deprotonated, and with negative 
charge, in alkaline solutions. Amino groups are known to be protonated at alkaline pHs, while 
carboxylic acids are known to be protonated at pHs lower than 4-5 as the pKa of these compounds 
is about 4.5. Adsorption and conjugation of gentamicin was expected to reduce the number of 
carboxyl groups on the surface of the carriers available for dissociation thus reducing the number of 
negative charges; analogously for amino groups the conjugation or adsorption of antibiotic would 
interfere with the ability of the nitrogen to be protonated and such reducing the number of positive 
charges on the surface of the carriers. The pH dependence of the nanoparticles (Figure 5) followed 
very well this description, providing further confirmation of the presence of either the desired 
groups or the antibiotic on the surface of the carriers. 
Two different pH buffers were employed to study the release of gentamicin from the nanocarriers 
to mimic two distinct situations: prevention of infection represented by physiological (pH = 7.4) 
conditions and treatment of established infections represented by acid conditions (pH = 5) [50]-
[52]. The release of gentamicin when entrapped into silica nanoparticles is not controlled as all the 
antibiotic that could be freed is released in the first hours of contact with aqueous solutions (Figure 
6); this is the consequence of the porosity of the nanocarriers that leads to water uptake. On the 
contrary, when gentamicin was adsorbed on unfunctionalised particles very little release was 
observed; at pH = 5 a greater amount of antibiotic was released from the particles than for pH = 7.4 
indicating that the adsorption of gentamicin is more stable in neutral conditions. Interestingly, not 
all antibiotic loaded in the particles through entrapment could be released from the nanocarriers, 
this could have been caused by the ability of the antibiotic molecules to migrate through a limited 
distance inside the particles resulting in only the molecules present on the outer layers to be 
released. This is the mechanism hypothesised to explain why only about 10% of gentamicin mixed 
in bone cement is released over time [53]. However, because of the limited thickness of the particles 
compared to bone cement this justification seem unlikely; alternatively it can be hypothesised some 
of antibiotic loaded through entrapment is effectively adsorbed on the surface of the silica 
nanoparticles and our results show that desorption from these carriers is difficult. Furthermore, in 
all cases not all the antibiotic initial present on the silica nanoparticles was released (Figure 6), even 
though not to the same extent as for the entrapped route; this seems to suggest that a certain amount 
of gentamicin can irreversibly bind to the silica surface. The higher adsorption of gentamicin onto 
silica at pH = 7.4 could also explain the lower total amount of antibiotic released from particles 
with entrapped antibiotic in this condition than in acidic environment. 
Functionalised particles appeared more suitable for providing antibiotic release for at least few 
days, remarkably no difference was noticed between conjugation of the antibiotic or its adsorption. 
Because the release from conjugated nanocarriers requires the hydrolysis of ester bonds, we 
expected that the kinetic of gentamicin release to be slower compared to the adsorption. Similar 
kinetic of release were reported from gentamicin conjugated onto the surface of functionalised gold 
nanoparticles through the formation of ester bonds [12]; this points towards the controlling role of 
the type of bond on the release kinetic of conjugated antibiotic on surfaces. The functionalisation of 
the particles had an extreme impact on the loading and desorption of gentamicin, when either amino 
(positively charged) or carboxyl (negatively charged) were present on the surface more antibiotic 
was adsorbed onto the surface and the release of gentamicin was almost complete compared to 
about 10% seen in unfunctionalised silica nanoparticles. Gentamicin is charged as it exhibit amino 
and hydroxyl groups; the adsorption was carried out at pH = 6 were the functionalised nanoparticles 
possessed surface charges facilitating the electrostatic interaction between particles and antibiotic 
enhancing the amount of drug adsorbed compared to unfunctionalised molecules.  
In this work, amino functionalised silica nanoparticles provided a positively charged substrate and 
we exploited the positive charge exhibited by gentamicin at physiological conditions, in virtue of 
the amino groups present on the molecule, to sandwich the antibiotic between alginate layers that 
are negatively charged. The choice of the polyelectrolytes used in this work (chitosan and alginate) 
was driven by the high biocompatibility of these biomacromolecules compared to other 
polyelectrolytes that are sometimes used for LbL i.e. poly(styrene sulfonate), poly(allylamine 
hydrochloride [54] and poly(diallyldimethyl ammonium chloride) [55]. 
Drug release from LbL coating can occur either through diffusion of the molecule across the 
polyelectrolytes layers or as result of deposited layers erosion [56], so called “delamination”. These 
two mechanisms also control the shape of the release profile; if LbL erosion is governing the 
release, then the cumulative amount of drug unbound increases linearly over time until a plateau is 
reached, corresponding to full LbL consumption. When diffusion of the drug through the layers is 
the controlling mechanism, the cumulative amount of drug follows a Fickian profile instead [56]. 
The release profile from our silica nanocarriers loaded through LbL (Figure 7c) depicts a 
mechanism controlled by drug diffusion, this mechanism is also the likely reason for the similar 
release kinetics at pH = 5 and pH = 7.4 as the acidity of the solution does not influence the diffusion 
of the drug through the deposited polyelectrolytes layers. Furthermore, the need to cross the 
different deposited layers results in the prolonged release of gentamicin compared to the other 
nanocarriers prepared in this work where the antibiotic is freely available.  
We have shown that silica nanocarriers loaded with gentamicin can be prepared through various 
protocols; depending on the preparation route, release of the drug can be tailored to different 
applications. For example, the complete release of the antibiotic in a few days appears suited for the 
treatment of local infections as it would allow the reduction of medications and thus improving 
patient compliance. On the other end, gentamicin release for many weeks is well suited for 
orthopaedic applications, such as encapsulation in bone cement. Because of the general nature of 
the phenomena employed in the preparation of our silica gentamicin nanocarriers (i.e. electrostatic 
forces and conjugation), it is easily foreseeable how the silica nanocarriers could be employed for 
the controlled delivery of other molecules.  
Other types of antibiotic releasing silica nanoparticles have been proposed, however in some no 
attempt was made to determine the effective period of time that the drug was release [57],[58], 
whilst in others only one preparation protocol was presented hence the role of the  protocol of 
synthesis in charactering the release was not established [59]. 
It is well known that the current mixing of antibiotics in bone cement is released only for the first 
few days after surgery [60], while infections can occur at the site even months after implantation 
[61]. Recently, antibiotics have been bound to silica nanocarriers either through conjugation [62] or 
co-precipitation [58] in order to provide controlled release. Despite the excellent blood 
compatibility and low toxicity demonstrated by these nanocarriers [62], the release was sustained 
for about 1 week; hence not as effective as the nanocarriers presented in this work. LbL has also 
been used to prepare antibiotic loaded silica nanocarriers [63],[64]. This approach was employed to 
entrap the drug under polyelectrolytes that enhance bacterial cell penetration [64] or to seal the drug 
inside mesoporous particles and, therefore, the polyelectrolytes acted as “gatekeeper” [49]; in this 
way sustained the release for about 10 days was achieved [63]; again not as effective as the 
nanocarriers presented in this work. 
Mesoporous silica nanoparticles (MSN) have been widely investigated as drug delivery vehicles 
[65]-[69] with their main benefit compared to nonporous nanoparticles being the higher surface 
available for drug loading. When surface conjugation or adsorption is carried out, the drug release 
kinetics is unlikely to depend on the presence of pores and the conclusions of our study can be 
translated to mesoporous silica nanoparticles. When LbL is utilised as gatekeeping the released is 
delayed, instead of sustained, as the drug entrapped in the pores has to cross the layers in order to 
become available. As shown by Tamanna et al. [63] with increasing number of polyelectrolytes 
layers the concentration of antibiotic release tend to present a lag phase.  
Nanocarriers based drug delivery systems for antibiotics require varying release kinetic according 
to the application they are design to fulfil; the desired release period can be from few days to weeks. 
We have shown the versatility of silica nanoparticles to be prepared as antibiotic delivery system 
and correlated the preparation protocol to the chosen release kinetics specification.  
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 Table 1. BET parameters and TGA total mass loss for different Si nanocarriers prepared. 
 
Sample BET surface area [m²/g] Total pore volume [cm3/g] TGA Mass loss (%) 
SiO2 65 ± 5 0.32 ± 0.04 14  ± 2 
SiO2 GS entrapped 78 ± 6 0.18 ± 0.03  31 ± 4 
SiO2 GS adsorbed 45 ± 4 0.35 ± 0.03  15 ± 2 
SiO2-NH2 48 ± 3 0.27 ± 0.05 17 ± 3 
SiO2-NH2 GS conjugated 48 ± 5 0.36 ± 0.03 19 ± 3 
SiO2-NH2 GS adsorbed 42 ± 7 0.32 ± 0.07 19 ± 4 
SiO2-COOH 41 ± 3 0.36 ± 0.05 17 ± 4 
SiO2-COOH GS conjugated 47 ± 6 0.31 ± 0.05 19 ± 3 
SiO2-COOH GS adsorbed 46 ± 4  0.44 ± 0.06 19 ± 4 
 
  
  
Figure 1. Reactions scheme involved in the nanocarriers preparation routes. 
 
 
 
 
 
  
Figure 2. Example of TEM image of unfunctionalised silica nanoparticles (a). Bar equivalent to 100 nm. 
Size distribution of unfunctionalised silica nanoparticles (columns) and corresponding Gaussian distribution 
(solid line) (b). 
  
  
Figure 3. Examples of nitrogen adsorption−desorption isotherm profiles of (a) silica nanoparticles and (b) 
silica with entrapped gentamicin. Adsorption is presented in blue and desorption in green. 
  
 Figure 4. Thermal Gravimetric Analysis (TGA) of silica nanocarriers unfunctionalised (a), amino 
functionalised (b) and succinylated (c). 
 unload nanoparticles    adsorbed gentamicin   conjugated gentamicin 
 entrapped gentamicin 
 
 
  
 Figure 5. Zeta potential of silica nanocarriers unfunctionalised (a), amino functionalised (b) and succinylated 
(c). 
unfunctionalised (), amino functionalised () and carboxyl acid functionalised (). Symbols filled in 
black for nanocarriers with conjugated gentamicin; symbols filled in gray for nanocarriers with adsorbed 
gentamicin; nanocarriers with entrapped gentamicin (). 
  
 Figure 6. Cumulative release of gentamicin from silica nanocarriers at pH =5 (a, b, c) and pH =7.4 (d, e, f) 
for unfunctionalised (circles), amino functionalised (squares) and carboxyl acid functionalised (triangles). 
Symbols filled in black for nanocarriers with conjugated gentamicin; empty symbols for nanocarriers with 
adsorbed gentamicin; symbols filled in grey for nanocarriers with entrapped gentamicin. 
  
Figure 7. Thermal Gravimetric Analysis (TGA) (a) and zeta potential (b) of silica nanocarriers after each 
deposited layer during LbL coating. Cumulative release of gentamicin (c) from silica nanocarriers coated 
through LbL at pH = 5 () and pH = 7.4 () 
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